Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Advanced Cancer 1

Interventions

Nivolumab 19 Ipilimumab 9 linrodostat 6 relatlimab 4 Pemetrexed 4 Paclitaxel 4 Carboplatin 4 ARRY-334543 4 Docetaxel 3 regorafenib 2 anlotinib 2 abemaciclib 2 N-(3,4-difluoro-2-(2-fluoro-4-iodophenylamino)-6-methoxyphenyl)-1-(2,3-dihydroxypropyl)cyclopropane-1-sulfonamide 2 Gemcitabine 2 Cyclophosphamide 2 Capecitabine 2 6-(6-(1-methyl-1H-pyrazol-4-yl)-(1,2,4)triazolo(4,3-b)pyridazin-3-ylsulfanyl)quinoline 2 vorolanib 1 trametinib 1 tislelizumab 1 sargramostim 1 ralimetinib 1 prexasertib 1 palifosfamide lysine 1 p38 Mitogen-Activated Protein Kinases 1 mirdametinib 1 lirilumab 1 indibulin 1 gedatolisib 1 fluzoparib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Advanced Cancer × fluorapacin × Clear all

NCT01361529 2011-05-27

Safety Study of FLP Injection to Treat Tumor Patients

Acea Bio (Hangzhou) Co., Ltd.

Phase 1 Unknown

Advanced Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡